Home > Pharmaceuticals and Healthcare > Global Cystic Fibrosis Therapeutics Market 2018-2022...

Global Cystic Fibrosis Therapeutics Market 2018-2022

No. of Pages: 111Published : 17 Jan 2018

Request Sample
 

About Cystic Fibrosis Therapeutics CF is a genetic disorder that mostly affects the lungs and sometimes other parts of the body such as the liver, pancreas, intestines, and the kidneys. The disease is inherited in an autosomal recessive manner. It is due to mutations caused in both the copies of the gene for the CFTR protein. Technavios analysts forecast the global cystic fibrosis therapeutics market to grow at a CAGR of 17.28% during the period 2018-2022. Covered in this report The report covers the present scenario and the growth prospects of the global cystic fibrosis therapeutics market for 2018-2022. To calculate the market size, the report presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources. The market is divided into the following segments based on geography: Americas APAC EMEA Technavio's report, Global Cystic Fibrosis Therapeutics Market 2018-2022, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market. Key vendors AbbVie Gilead F. Hoffmann-La Roche Vertex Pharmaceuticals Market driver Improved diagnostic technologies For a full, detailed list, view our report Market challenge Drug discontinuation For a full, detailed list, view our report Market trend Strategic collaborations For a full, detailed list, view our report Key questions answered in this report What will the market size be in 2022 and what will the growth rate be? What are the key market trends? What is driving this market? What are the challenges to market growth? Who are the key vendors in this market space? You can request one free hour of our analysts time when you purchase this market report. Details are provided within the report.

 

Table of Contents PART 01: EXECUTIVE SUMMARY PART 02: SCOPE OF THE REPORT PART 03: RESEARCH METHODOLOGY PART 04: INTRODUCTION Market outline PART 05: MARKET LANDSCAPE Market ecosystem Market characteristics Market segmentation analysis PART 06: MARKET SIZING Market definition Market sizing Market size and forecast PART 07: FIVE FORCES ANALYSIS Bargaining power of buyers Bargaining power of suppliers Threat of new entrants Threat of substitutes Threat of rivalry Market condition PART 08: MARKET SEGMENTATION BY DRUG CLASS Comparison by drug class CFTR modulators Mucolytics PERT Anti-infectives Bronchodilators Market opportunity by drug class PART 09: CUSTOMER LANDSCAPE PART 10: REGIONAL LANDSCAPE Regional comparison CF therapeutics market in Americas CF therapeutics market in EMEA CF therapeutics market in APAC Market opportunity PART 11: DECISION FRAMEWORK PART 12: DRIVERS AND CHALLENGES Market Drivers Market challenges PART 13: MARKET TRENDS Strategic collaborations Advances in technology for drug development and delivery PART 14: VENDOR LANDSCAPE Overview Landscape disruption Competitive scenario PART 15: VENDOR ANALYSIS Vendors covered Vendor classification Market positioning of vendors AbbVie Gilead F. Hoffmann-La Roche Vertex Pharmaceuticals PART 16: APPENDIX List of abbreviations List of Exhibits Exhibit 01: Autosomal recessive pattern of inheritance in CF Exhibit 02: Effects of CF on different body parts Exhibit 03: Most common CFTR mutations Exhibit 04: Global birth prevalence of CF by 2017 Exhibit 05: Diagnosis and treatment of CF Exhibit 06: Parent market Exhibit 07: Market characteristics Exhibit 08: Market segments Exhibit 09: Market definition: Inclusions and exclusions checklist Exhibit 10: Market size Exhibit 11: Validation techniques employed for market sizing 2017 Exhibit 12: Global CF therapeutics market 2017-2022 ($ millions) Exhibit 13: Global CF therapeutics market: Year over year growth 2018-2022 (%) Exhibit 14: Five forces analysis 2017 Exhibit 15: Five forces analysis 2022 Exhibit 16: Bargaining power of buyers Exhibit 17: Bargaining power of suppliers Exhibit 18: Threat of new entrants Exhibit 19: Threat of substitutes Exhibit 20: Threat of rivalry Exhibit 21: Market condition: Five forces 2017 Exhibit 22: Global CF therapeutics market by drug class 2017-2022 (% share) Exhibit 23: Comparison by drug class Exhibit 24: Global CF therapeutics market by CFTR modulators 2017-2022 ($ millions) Exhibit 25: KALYDECO description Exhibit 26: ORKAMBI description Exhibit 27: Global CF therapeutics market by CFTR modulators: Year over year growth 2018-2022 (%) Exhibit 28: Global CF therapeutics market by mucolytics 2017-2022 ($ millions) Exhibit 29: Global CF therapeutics market by mucolytics: Year over year growth 2018-2022 (%) Exhibit 30: Global CF therapeutics market by PERT 2017-2022 ($ millions) Exhibit 31: Global CF therapeutics market by PERT: Year over year growth 2018-2022 (%) Exhibit 32: Global CF therapeutics market by anti-infectives 2017-2022 ($ millions) Exhibit 33: Global CF therapeutics market by anti-infectives: Year over year growth 2018-2022 (%) Exhibit 34: Global CF therapeutics market by bronchodilators 2017-2022 ($ millions) Exhibit 35: Global CF therapeutics market by bronchodilators: Year over year growth 2018-2022 (%) Exhibit 36: Market opportunity by drug class Exhibit 37: Customer landscape Exhibit 38: Global CF therapeutics market by region 2017-2022 (% share) Exhibit 39: Regional comparison Exhibit 40: CF therapeutics market in Americas 2017-2022 ($ millions) Exhibit 41: CF therapeutics market in Americas: Year over year growth 2018-2022 (%) Exhibit 42: Top three countries in Americas Exhibit 43: CF therapeutics market in EMEA 2017-2022 ($ millions) Exhibit 44: CF therapeutics market in EMEA: Year over year growth 2018-2022 (%) Exhibit 45: Top three countries in EMEA Exhibit 46: CF therapeutics market in APAC 2017-2022 ($ millions) Exhibit 47: CF therapeutics market in APAC: Year over year growth 2018-2022 (%) Exhibit 48: Top three countries in APAC Exhibit 49: Market opportunity Exhibit 50: Few drugs with breakthrough therapy designation for CF Exhibit 51: Few drugs with Orphan Drug Designation for CF Exhibit 52: Few CF therapeutics discontinued from development Exhibit 53: Partnerships and collaborations between companies for development of CF therapeutics Exhibit 54: Vendor landscape Exhibit 55: Landscape disruption Exhibit 56: Competitive structure analysis of global CF therapeutics market 2017 Exhibit 57: Vendors covered Exhibit 58: Vendor classification Exhibit 59: Market positioning of vendors Exhibit 60: AbbVie: Overview Exhibit 61: AbbVie: Business segments Exhibit 62: AbbVie: Organizational developments Exhibit 63: AbbVie: Geographic focus Exhibit 64: AbbVie: Segment focus Exhibit 65: AbbVie: Key offerings Exhibit 66: AbbVie: Key customers Exhibit 67: Gilead: Overview Exhibit 68: Gilead: Business segments Exhibit 69: Gilead: Organizational developments Exhibit 70: Gilead: Geographic focus Exhibit 71: Gilead: Segment focus Exhibit 72: Gilead: Key offerings Exhibit 73: Gilead: Key customers Exhibit 74: F. Hoffmann-La Roche: Overview Exhibit 75: F. Hoffmann-La Roche: Business segments Exhibit 76: F. Hoffmann-La Roche: Organizational developments Exhibit 77: F. Hoffmann-La Roche: Geographic focus Exhibit 78: F. Hoffmann-La Roche: Segment focus Exhibit 79: F. Hoffmann-La Roche: Key offerings Exhibit 80: F. Hoffmann-La Roche: Key customers Exhibit 81: Vertex Pharmaceuticals: Overview Exhibit 82: Vertex Pharmaceuticals: Business segments Exhibit 83: Vertex Pharmaceuticals: Organizational developments Exhibit 84: Vertex Pharmaceuticals: Geographic focus Exhibit 85: Vertex Pharmaceuticals: Segment focus Exhibit 86: Vertex Pharmaceuticals: Key offerings Exhibit 87: Vertex Pharmaceuticals: Key customers

Technavio presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources. The analysts have presented the various facets of the market with a particular focus on identifying the key industry influencers. The data thus presented is comprehensive, reliable, and the result of extensive research, both primary and secondary.
 

 INFORMATION SOURCES:

Primary research - Manufacturers/Suppliers, Channel partners, Industry experts, Strategic decision makers
 

Secondary research - Technavio internal repository, Industry journals and periodicals, Government bodies, Annual reports of key stakeholders
 

DATA ANALYSIS:

Data synthesis - Collation of data, Estimation of key figure, Analysis of derived insights
 

Data validation - Triangulation with data models, Reference against proprietary databases, Corroboration with industry experts
 

REPORT WRITING

Qualitative analysis - Market drivers, Market challenges, Market trends, Five forces analysis
 

Quantitative analysis- Market size and forecast, Market segmentation, Geographical insights, Competitive landscape
 

Technavio’s database and industry-specific repositories are used for defining the hypothesis for the study, which is further fine-tuned through primary research involving industry experts. The success of our approach lies in the fact that we take the viewpoint of all stakeholders into consideration while analyzing an industry, and objectively assess each outlook. 
 

Report ID : MSF483593

Publisher Name : Technavio

Why Market Size Forecasters?

  • Reports at Lowest Prices - Guaranteed
  • Fastest Growing Research Reports’ Database
  • Easy Customization Options
  • 24 X 7 Support Commitment
  • Certified, Safe & Secured Payments

Have A Question?

Ask UsView FAQ's